News
-
Civitas Therapeutics has announced that all of its existing investors, plus seven new investors, participated in a $55 million Series C financing round. The company is developing products based on respiratory delivery technology acquired from… Read more . . .
-
The Medicon Valley Inhalation Consortium (MVIC) has announced that Ola Nerbrink has succeeded Orest Lastow as CEO. Nerbrink was previously MVIC’s VP of Business Development. Lastow, who founded MVIC in 2012, left the position in… Read more . . .
-
Molins Technologies has announced the addition of the disk format µ-check to their µ-check line of check weighers. The standard µ-check can weigh individual DPI blisters alone or in blister strips. The new µ-check machine… Read more . . .
-
Sandoz has announced that the Mexican health authority, COFEPRIS, has approved the company’s marketing application for the Airflusal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and for COPD. Three dosage levels were approved: 50-100… Read more . . .
-
GlaxoSmithKline has announced that it has received FDA approval for its fluticasone furoate DPI, to be marketed as Arnuity Ellipta, for the maintenance treatment of asthma. The approval is for 100mcg and 200mcg doses and… Read more . . .
-
The FDA has accepted Boehringer Ingelheim’s New Drug Application for its tiotropium/olodaterol Respimat soft mist inhaler for the treatment of COPD, the company has announced. BI’s Striverdi Respimat olodaterol SMI was approved by the FDA… Read more . . .
-
The United States Pharmacopeial Convention (USP) has announced three recipients of its 2014–2015 Global Fellowship Awards. One of the recipients of the $30,000 fellowship, Ahmed Shalash of Alexandria University in Alexandria, Egypt, is researching carriers… Read more . . .
-
In addition to its 20% acetylcysteine solution products, Fresenius Kabi is now offering 4 ml, 10 ml, and 30 ml vials of acetylcysteine 10% for oral use or inhalation in the US. Acetylcysteine is a… Read more . . .
-
The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 10-3 to approve Boehringer Ingelheim’s Spiriva Respimat tiotropium soft mist inhaler for the treatment of COPD. BI’s first NDA submission for tiotropium Respimat took place in… Read more . . .
-
Skyepharma says that it will begin developing a COPD therapy based on Pulmagen’s ICS “re-sensitization” technology (SKP-2075) by the end of 2014 after acquiring the IP and global rights to the Theocort platform from Pulmagen.… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.